Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
4.450
+0.020 (0.45%)
At close: Mar 6, 2026, 4:00 PM EST
4.500
+0.050 (1.12%)
After-hours: Mar 6, 2026, 5:51 PM EST
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 3 or -15.00% compared to the previous year.
Employees
17
Change (1Y)
-3
Growth (1Y)
-15.00%
Revenue / Employee
n/a
Profits / Employee
-$3,304,385
Market Cap
326.33M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Adlai Nortye | 123 |
| Foghorn Therapeutics | 112 |
| Rezolute | 75 |
| Immuneering | 54 |
| Shattuck Labs | 44 |
| Protara Therapeutics | 33 |
RLMD News
- 7 weeks ago - Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - GlobeNewsWire
- 3 months ago - Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewsWire
- 4 months ago - Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates - GlobeNewsWire
- 4 months ago - Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 - GlobeNewsWire
- 4 months ago - Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 months ago - Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer - GlobeNewsWire
- 5 months ago - Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - GlobeNewsWire